This HCPLive Peer Exchange series provides a comprehensive evaluation of Wilson disease, from its underlying pathophysiology and clinical manifestations to the diagnostic criteria that impact long-term patient quality of life. The panelists analyze the safety and efficacy of current and emerging therapeutic paradigms while offering practical, data-driven strategies to overcome management challenges and improve medication adherence.
Panelists discuss the often subtle and asymptomatic hepatic presentations of Wilson disease, emphasizing the importance of early detection, awareness of advanced complications, and maintaining clinical suspicion to prevent progression to severe liver outcomes.
Panelists discuss the often misdiagnosed neurological and psychiatric manifestations of Wilson disease, highlighting its overlap with common movement and mental health disorders, the need for high clinical suspicion, and the importance of early diagnosis through careful evaluation of overlapping symptoms.
Wilson disease mimics tremor, dystonia, Parkinsonism or psychosis; watch for subtle liver signs and screen early to avoid delay.
Learn how subtle liver enzyme changes and age-specific movement symptoms signal Wilson disease, plus the latest on newborn screening and tests.
Learn how subtle liver labs and movement changes trigger early Wilson disease testing, from newborn screening to MRI and copper assays.
Learn how Leipzig scoring and genetic testing, plus labs and eye exams, help diagnose pediatric Wilson disease when symptoms are subtle.
Newborn screening spots Wilson’s disease sooner, helping stop copper buildup and irreversible neurologic damage—improving outcomes and daily life.
Learn how chelators and zinc manage copper in Wilson disease, why trientine is favored, and when maintenance therapy becomes lifelong.
New copper chelator offers twice-daily, room-temp dosing and stable results vs penicillamine, boosting adherence for Wilson disease care.
Learn key chelation therapy risks—penicillamine skin and lupus-like reactions, zinc GI upset, trientine tolerability—and adherence tips.
How experts track Wilson disease symptoms, fine-tune chelation or zinc, and use tremor, dystonia therapies to protect quality of life.
New ATP7B gene therapies aim to normalize copper in Wilson’s disease, reducing chelation needs while raising durability and patient-selection questions.
Explore why Wilson’s disease patients stop lifelong therapy and how simpler, better-tolerated dosing improves adherence, preventing relapse and severe liver outcomes.
Clinicians share practical ways to boost lifelong Wilson disease treatment adherence—education, monitoring, and team-based transition support.
